As the Ebola outbreak continues to claim victims in West Africa, governments and industry alike are racing toward a therapeutic or preventive drug that could help halt its deadly spread and avert future human crises involving the virus.
Scientists have pinpointed a protein that plays a role in protection against Mycobacterium tuberculosis in people who are infected with the pathogen.
Stanford bioengineers are designing an opioid-based medication that can treat pain effectively without the need to grow actual poppies. The research could provide an alternative production method to growing poppies, which aren't found in the U.S.
Using reprogrammed cells taken from a mouse, scientists have grown a fully functional organ and successfully transplanted it into a living animal for the first time.
Big Pharma has largely exited the antibiotics arena in the past several years, contributing to the dearth of products in the global pipeline as rising antimicrobial resistance becomes a very real public health threat.
Drug development bottlenecks are typical and inevitable in clinical trials, but there may be more holdups during the discovery and preclinical phase than previously thought, according to a new study.
Many experimental Alzheimer's therapies have tried--and failed---to reverse or halt symptoms of the neurodegenerative disease by targeting the protein amyloid β in the brains of affected individuals. New research suggests that another culprit may be behind the development of Alzheimer's.
Novartis is transferring its full tuberculosis research and development program to the nonprofit TB Alliance, according to a company statement.
A new strategy that uses broadly neutralizing antibodies combined with a cocktail of viral-inducing compounds may be able to stop HIV from rebounding, according to researchers at Rockefeller University.
Scientists have linked a single enzyme to the development of diabetes, a finding that could help develop new treatments for the more than 120 million Americans that have diabetes or pre-diabetes.
A bacteria-based injectable therapy shrunk tumors and completely eradicated others when tested in dogs and rats, according to a new study.
A new lung-on-a-chip microdevice developed by a team of nonprofit and academic researchers could help scientists better study respiratory disorders and test new therapeutics more accurately than in animal models.
Organovo's 3-D Human Liver System was able to correctly detect the toxicity of a drug that standard preclinical animal studies and in vitro toxicity tests had previously deemed safe but caused liver damage in clinical use.
New research may shed some light on how the Ebola virus ravages the immune system and point to ways to stop the disease in its tracks.
As resistance to many currently available antibiotics grows, health officials have been on high alert to bacteria that are rapidly adapting and becoming so-called superbugs. Scientists have discovered one such pathogen, called Pseudomonas aeruginosa, in patient samples in Ohio, underscoring the need for better surveillance and monitoring of drug-resistant bugs.
Investigators from Tufts University have developed and grown complex 3-D brainlike tissue from rats, keeping it alive in a laboratory setting for two months.
Researchers have used a new drug compound to successfully reverse brain deficits caused by Alzheimer's in animal models. The compound, TC-2153, inhibits the negative effects of a protein called striatal-enriched tyrosine phosphatase--a process that scientists found is key to restoring functions in learning and memory.
A vaccine to protect against malaria had long evaded researchers up until GlaxoSmithKline's submission of its vaccine to the European Medicines Agency. But even the drug giant's candidate against the mosquito-borne scourge has shown only modest protection, underscoring the need for better treatments.
British drugmaker GlaxoSmithKline says it is ready to begin clinical trials on an Ebola vaccine later this year and could have the vaccine available by 2015.
Using a gene-editing method, investigators were able to delete certain genes in the human papillomavirus, prompting cancer-causing cells to self-destruct. The antiviral technique could be replicated to target other DNA-based viruses like hepatitis B and herpes simplex, researchers say.